Publication:
Folic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptor

Simple item page
dc.contributor.authorFuster, M. G.
dc.contributor.authorMontalbán, M. G.
dc.contributor.authorMoulefera, I.
dc.contributor.authorVíllora Cano, Gloria
dc.contributor.authorKaplan, D. L.
dc.contributor.departmentIngeniería Químicaes
dc.contributor.otherFacultad de Químicaes
dc.date.accessioned2025-07-17T08:36:07Z
dc.date.available2025-07-17T08:36:07Z
dc.date.issued2023-04-07
dc.description© 2023 by the authors____ This document is the published version of a published work that appeared in final form in Pharmaceutics____ This document is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0 ____ To access the final edited and published work see: https://doi.org/10.3390/pharmaceutics15041186
dc.description.abstractThe anticancer drug ibrutinib (IB), also known as PCI-32765, is a compound that irreversibly inhibits Bruton’s tyrosine kinase (BTK) and was initially developed as a treatment option for B-cell lineage neoplasms. Its action is not limited to B-cells, as it is expressed in all hematopoietic lineages and plays a crucial role in the tumor microenvironment. However, clinical trials with the drug have resulted in conflicting outcomes against solid tumors. In this study, folic acid-conjugated silk nanoparticles were used for the targeted delivery of IB to the cancer cell lines HeLa, BT-474, and SKBR3 by exploiting the overexpression of folate receptors on their surfaces. The results were compared with those of control healthy cells (EA.hy926). Cellular uptake studies confirmed total internalization of the nanoparticles functionalized by this procedure in the cancer cells after 24 h, compared to nanoparticles not functionalized with folic acid, suggesting that cellular uptake was mediated by folate receptors overexpressed in the cancer cells. The results indicate that the developed nanocarrier can be used for drug targeting applications by enhancing IB uptake in cancer cells with folate receptor overexpression.
dc.formatapplication/pdfes
dc.format.extent26
dc.identifier.citationPharmaceutics. 2023 Apr 7 15(4):1186.
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics15041186
dc.identifier.issn1999-4923
dc.identifier.urihttp://hdl.handle.net/10201/157509
dc.languageenges
dc.publisherMDPIes
dc.relationPROYECTO 1 Ámbito del proyecto: nacional Agencia financiadora: Agencia estatal de investigación y Ministerio de Ciencia, Innovación y Universidades Convocatoria: 2020 Nombre del proyecto: BIOMATERIALES EN NANOINGENIERÍA: PRODUCCIÓN Y APLICACIONES EN TERAPIAS ANTICANCERÍGENA, ANTIBACTERIANA Y ANTIVIRAL Código o número del acuerdo de subvención: PID2020-113081RB-I00es
dc.relation.publisherversionhttps://www.mdpi.com/1999-4923/15/4/1186
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectSilk fibroin
dc.subjectFolate receptor
dc.subjectBrutinib
dc.subjectNanoparticles
dc.subjectCancer
dc.subjectHeLa
dc.subjectBT-474
dc.subjectSKBR3
dc.subjectEA.hy926
dc.titleFolic Acid-Modified Ibrutinib-Loaded Silk Fibroin Nanoparticles for Cancer Cell Therapy with Over-Expressed Folate Receptores
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
pharmaceutics-15-01186-10.pdf
Size:
13.93 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos